

Financial Tear Sheet

Corporate Profile


Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Stock Performance

OVID (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$6.45
Change (%)	▼ 0.09 (1.38%)
Volume	48,808
52 Week High	\$15.93
52 Week Low	\$5.28
Market Cap	\$160,896,661
Rolling EPS	-4.50
PE Ratio	0
Shares Outstanding	24,601,936

Data as of August 16, 2017 4:00 p.m. ET



Recent Headlines

August 10, 2017

Ovid Therapeutics Reports Second Quarter 2017
Financial Results and Corporate Progress

June 23, 2017

Ovid Therapeutics to be Added to Russell 2000®,
3000® and Microcap® Indexes

June 14, 2017

Ovid Therapeutics Appoints Barbara G. Duncan to
its Board of Directors

SEC Filings

Filing Date	Form
August 15, 2017	8-K
August 10, 2017	8-K
August 10, 2017	10-Q
June 22, 2017	8-K

Upcoming Events

There are currently no events scheduled.

Corporate Governance

Jeremy Levin, D.Phil., MB BChir	Chairman of the Board of Directors
------------------------------------	--

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.